AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before.
To join the study, participants must meet the following conditions:
* Be 18 years or older.
* Have colorectal cancer that has spread to other parts of your body.
* Be in good enough health to receive study treatment.
* Should not be pregnant before starting treatment.
Participants will be randomized (like flipping a coin) to one of 2 different treatment arms. The first arm (Arm A) will include the new medicine PF-08634404 in combination with chemotherapy that is approved for colorectal cancer, and the second arm (Arm B) will include an approved medicine for colorectal cancer, called Bevacizumab, in combination with chemotherapy that is approved for this type of cancer. Participants and their doctors will not know which arm they are being assigned to. Participants will receive all the study medications through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, and participants may continue receiving it if it is helping and they are not experiencing serious side effects.
The medicine will be given at a clinical site, where trained medical staff will check participants during and after each treatment.
* The study is expected to last approximately 33 months for each participant.
* Participants will have regular visits to the study site for treatment, health checks, and tests.
* After stopping treatment, participants will return for a final visit about 30 to37 days later to check their health and review any side effects.
* Follow-up will continue every 12 weeks by phone or in person or by reviewing health records to check on health status and any new treatments.

Start Date12 Dec 2025

Sponsor / Collaborator

Pfizer Inc.

NCT07222566

/ Not yet recruitingPhase 3

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
* Be 18 years or older.
* Have locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC.
* Is not a candidate for complete surgical resection or curative chemoradiotherapy.
* Do not have known actionable genomic alterations
* Be treatment naïve for advanced or metastatic disease
Participants in this study will be assigned to two different parts of the study depending on their type of tumor: participants with squamous NSCLC will be assigned to Part 1, while participants with non-squamous NSCLC will be assigned to Part 2.
Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups in a blinded fashion:
* Part 1 - Arm A or Part 2 - Arm C (Experimental Group): Will receive a new study medicine called PF-08634404 along with a kind of chemotherapy specific to the type of tumor.
* Part 1 - Arm B or Part 2 - Arm D (Control Group): Will receive an approved medicine called pembrolizumab along with a kind of chemotherapy specific to the type of tumor.
Participants will receive their assigned treatment through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, participants will receive PF-08634404 or Pembrolizumab in combination with chemotherapy followed by maintenance with either PF-08634404 or Pembrolizumab monotherapy (Part 1) or PF-08634404 or Pembrolizumab in combination with a chemotherapeutic drug (Part 2). Participants will continue receiving treatment if it is helping and not experiencing serious side effects.
The study will include regular visits for:
* Treatment and health checks: while participant continues receiving treatment.
* Tests to monitor how cancer responds: every 6 weeks during the first 48 weeks, then every 12 weeks thereafter.

Start Date05 Dec 2025

Sponsor / Collaborator

Pfizer Inc.

NCT07227415

/ Not yet recruitingPhase 1/2

AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them.
To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer.
Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.

Start Date04 Dec 2025

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with SSGJ-707

100 Translational Medicine associated with SSGJ-707

100 Patents (Medical) associated with SSGJ-707

News (Medical) associated with SSGJ-707

12 Nov 2025

·endpoints.news

After a frenzied year of dealmaking, here’s how the PD-(L)1xVEGF bispecific race is looking so far

The competitive landscape for PD-(L)1xVEGF bispecifics is finally taking shape. For the last couple years, much of the attention has focused on Summit Therapeutics and its lead drug ivonescimab. Now, two other challengers are revving their engines, setting up a race that may shape the future of immuno-oncology. If successful, the companies could bring new treatments to a plethora of cancer patients in the next decade. The biggest impact will likely be in areas like colorectal cancer, where PD-(L)1 checkpoint inhibitors are not widely used and some experts see untapped potential . But each bispecific will also be attempting to replace those PD-(L)1 drugs, like Merck’s $30-billion-a-year blockbuster Keytruda, in certain cancers where they’ve long been the standard. Summit’s first rival is the team of Pfizer and 3SBio, which signed a licensing deal for a PD-1xVEGF bispecific called SSGJ-707 earlier this year. Pfizer unveiled the first look at its clinical development plan in a presentation with analysts on Monday for the newly named PF’4404. Among other trials, that candidate will be in a Phase 3 study in first-line metastatic colorectal cancer and a Phase 3 non-small cell lung cancer study evaluating both squamous and non-squamous tumors. Jeff Legos, Pfizer’s chief oncology officer, took note of the “substantial opportunity” in colorectal cancer on the analyst call. He also emphasized roughly 95% of colorectal cancer patients aren’t eligible to receive checkpoint inhibitors like Keytruda. “These patients will be the focus of our planned ‘4404 Phase 3 studies in metastatic CRC,” Legos said. The other main competitors, Bristol Myers Squibb and BioNTech, teamed up this past June for a deal worth up to $11.1 billion. The pair is advancing a PD-L1xVEGF program called pumitamig that BioNTech acquired in its Biotheus buyout . After Bristol Myers outlined a suite of five mid- and late-stage studies during an earnings call last month, BioNTech went further at its R&D Day on Tuesday and provided perhaps the most in-depth look at what’s coming next. Beyond colorectal and triple-negative breast cancer — where other companies have not disclosed trial plans — BioNTech is looking at an amalgam of studies in difficult indications. That includes pancreatic cancer, ovarian cancer and glioblastoma, where BioNTech plans to start Phase 1 or Phase 2 studies in the coming years. Both the Pfizer-3SBio and BMS-BioNTech groups are planning to use their respective pipelines at their disposal to create what they hope are potent combination therapies. Pfizer is planning on testing PF’4404 with the antibody-drug conjugates it got from Seagen, Endpoints News previously reported , while BMS and BioNTech have flexibility in their deal to run studies combining pumitamig with experimental drugs in each of their portfolios. For pumitamig, that will involve combo therapies with BioNTech’s in-house assets, as well as other partnered drugs from DualityBio, OncoC4 and MediLink, BioNTech CEO Uğur Şahin told Endpoints in an interview on Tuesday. Bristol Myers will also be able to run trials with pumitamig and some of its own pipeline programs. “Both parties have the opportunity to develop, and even do registrational trials, with their own compound combinations,” Şahin said. “But both partners have also the ability to join into existing combination trials of the other party. So this is a really permissive approach for drug development, and does not rely on having to discuss everything and agree on every detail before you start something.” Despite all the momentum this year, whether these development plans work may not be known for a while. Summit plans to file for an ivonescimab approval in a certain form of non-small cell lung cancer, though the market size is estimated to be about just $500 million. Summit also announced last month it would start its own colorectal cancer trial and plot a course of combination therapy studies; enrollment in colorectal cancer is slated to start by the end of the year. Meanwhile, the earliest Phase 3 pumitamig data from BMS-BioNTech are not expected until 2028. Additionally, results from the two PF’4404 Phase 3 trials Pfizer announced won’t come until 2029 or 2030 , according to the ClinicalTrials.gov database. Although those data are a few years away, they are coincidentally timed to read out around when Keytruda will fall off-patent in 2028. (Merck also has its own PD-1xVEGF bispecific partnership with LaNova Medicines, but that program is in a much earlier stage of development — it just started a Phase 1 China trial last year.) Other earlier-stage trials for PF’4404 may report results in the meantime, potentially giving the industry its first clues as to whether this new class of drugs can work outside lung cancer. Pfizer didn’t provide an exact timeline for data, saying only that Phase 1/2 studies in liver, urothelial and kidney cancers will start in 2026. Pumitamig, however, will certainly have additional data by the time Keytruda falls off-patent. Phase 2 results in first-line lung cancer are expected next year, and a Phase 3 China study in triple-negative breast cancer should also read out in 2026. Even though positive China data might not correlate to a similar result in Western patients — Summit faced scrutiny over this issue in its lung cancer studies — BioNTech executives are confident breast cancer can be different. “We believe there should be no difference in other indications,” Ilhan Celik, VP of clinical development, said at the BioNTech R&D Day on Tuesday. “This will be, again, guided by the data, but there is no reason to believe that there are significant differences regarding the response and the efficacy. Safety, by the way, is also very similar.” TD Cowen analyst Yaron Werber wrote in a note to investors Wednesday morning that the key for BioNTech will be ensuring it can stay on these timelines, particularly since most of the spaces they’re playing in are very competitive. “There is a lot here to drive interest, but we note that the company has historically had some slippage of timelines (including global dose finding readouts for pumi) or outright attrition for pipeline assets,” Werber wrote. “Hence, we will be looking to see whether mgmt will be able to keep to the schedule they set forward.” Editor’s note: This article has been updated to correct that the total value of BioNTech and Bristol Myers’ collaboration is $11.1 billion, not $10.6 billion.

License out/inPhase 3Phase 2Phase 1ADC

11 Nov 2025

·www.fiercebiotech.com

With Summit leading the pack in PD-1xVEGF bispecifics, Pfizer lays out its own plan to replace Keytruda

Pfizer on Monday unveiled seven anticipated near-term clinical trials for its PD-1xVEGF bispecific antibody PF-08634404.\n As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its newly acquired PD-1xVEGF drug as a new cornerstone of cancer immunotherapy.The New York pharma on Monday unveiled seven near-term trials of its PD-1xVEGF bispecific antibody, the first of what chief oncology officer Jeff Legos, Ph.D., called “many planned waves” of clinical investigation into PF-08634404, also known as SSGJ-707, in various cancer types.“We believe that ’4404 is a foundational asset and a strong, seamless fit with Pfizer’s oncology strategy,” Legos said on a Nov. 10 investor call, the second of its kind focused on the bispecific in less than four months after Pfizer closed its potential $6 billion deal with the drug’s original developer, China’s 3SBio, in late July.“We are laser-focused on developing ’4404 with speed, with breadth and depth,” he added.Two global phase 3 trials have already been registered with ClinicalTrials.gov. These include a high-stakes head-to-head study against Merck & Co.’s PD-1 king Keytruda in first-line non-small cell lung cancer. The study, which will enroll 1,500 patients across nonsquamous and squamous subtypes, will pit PF-08634404 and chemotherapy against Keytruda-chemo regimens, which are the current standard of care. The dual primary endpoints of the study are progression-free survival and overall survival, according to Legos.The launch of this trial unavoidably puts Pfizer/3SBio on a collision course with Summit Therapeutics/Akeso’s ivonescimab and Bristol Myers Squibb/BioNTech’s pumitamig, two other PD-(L)1xVEGF drugs in phase 3 testing in first-line NSCLC. Pfizer built its confidence in its phase 3 approach for PF-08634404 based on results from a phase 2 trial conducted by 3SBio in China. In the study, treatment with the bispecific at 10 mg/kg and chemo yielded an overall response rate (ORR) of 58.6% in patients with nonsquamous NSCLC. Further, the ORR was 69.2% among those with squamous disease who were treated with the bispecific when the chemo partner was nab-paclitaxel and 37.5% when paclitaxel was the combo partner.The ORR for the squamous population was calculated after a “considerably shorter” follow-up period, Legos noted. The results were presented at the Society for Immunotherapy of Cancer 2025 annual meeting during this past weekend.By comparison, in the same study, a combination of BeOne Medicines’ PD-1 inhibitor Tevimbra and chemo yielded a 38.7% ORR in nonsquamous patients and 28.6% in squamous participants.Grade 3 or above treatment-related adverse events occurred in 39% of patients receiving the 3SBio bispecific at 10 mg/kg and 32.8% receiving Tevimbra.Summit/Akeso’s first-in-class PD-1xVEGF bispecific ivonescimab has already reported phase 3 data—albeit from a China-only study—in combination with chemo in patients with untreated NSCLC. In the phase 3 HARMONi-6 trial, which enrolled patients with first-line squamous NSCLC, ivonescimab and chemo reduced patients’ risk of progression or death by 40% compared with Tevimbra and chemo, according to results presented last month at the 2025 European Society for Medical Oncology Congress.The ORR was 75.9% for the ivonescimab arm in that trial. On Monday’s call, Pfizer’s PF-08634404 franchise lead, Arati Rao, M.D., described the two bispecific drugs’ ORR numbers as very similar, considering the Pfizer trial’s small size and short follow-up time. Pfizer expects similar results as it expands into a larger study, Rao explained.But as Citi analyst Geoff Meacham noted on the call, the all-important first-line NSCLC field is getting crowded with next-generation candidates. That’s why Pfizer hopes that after establishing PF-08634404’s profile alongside the existing standard of care, “the next wave of innovation will move into novel combinations,” Legos said.One of Pfizer’s planned phase 1/2 studies will see the company combine PF-08634404 with its antibody-drug conjugates in NSCLC.The second phase 3 trial for PF-08634404 will again see Pfizer eying similar territory as rivals Summit/Akeso and BioNTech/BMS. Pfizer’s planned 800-subject study will evaluate PF-08634404 and chemo against bevacizumab and chemo in patients with first-line metastatic colorectal cancer that’s not BRAF-mutated or microsatellite instability-high. Again, plans are underway to evaluate the two other rival PD-(L)1xVEGF drugs in phase 3 trials in the same setting.If the NSCLC trial can be viewed as Pfizer’s attempt to prove PF-08634404 as a better immunotherapy than Keytruda, then the mCRC study is designed to showcase the drug as a better anti-angiogenic agent than bevacizumab. But rather than having industry watchers read between the lines, Legos made it perfectly clear: “We’re aiming to make ’4404 a key part of our future oncology arsenal by displacing the current standard of care PD-1 and PD-L1 and VEGF agents with a new PD-1xVEGF bispecific backbone therapy across multiple tumor types.”Beyond those two studies, Pfizer is planning a phase 2/3 in front-line extensive-stage small cell lung cancer, a field where BioNTech and BMS seem to be leading with their global Rosetta-Lung01 trial. In Pfizer’s planned study, the primary endpoint of the phase 3 portion will be overall survival. There’s an unsubstantiated perception within the oncology community that existing PD-1 inhibitors aren’t that different from one another, and that Keytruda became king with the most successful clinical results because of subtleties related to patient selection and enrollment. As the competition now extends to the PD-(L1)xVEGF class, the question naturally arises whether Pfizer can leverage such an advantage for its agent, TD Cowen analyst Steve Scala asked on Monday’s call.Legos argued that Pfizer’s expertise in cancer drug development, including an established clinical trial footprint and relationships with investigators, will help the company in its clinical endeavors. Pfizer has identified more than 500 clinical centers it has worked with in previous studies that have confirmed their willingness to participate in PF-08634404’s phase 3 trials, Legos said.“We believe that we will be able to reach and target patients that are truly representative of those which we are seeking an indication in, including both the United States, Europe and Asia,” he said.Pfizer’s three remaining studies with near-term starts are phase 1/2 trials in liver cancer, bladder cancer and kidney cancer.“These seven anticipated near-term study starts are only the beginning of our plans for ’4404,” Legos said. “We’re actively working through a second wave of potential development opportunities that could deal trial starts for another 10 additional indications and 10 or more novel combinations before the end of 2026, which is a good segue to how we’re thinking about our depth of development across settings, across lines of therapies, including novel combinations.”

Phase 3Clinical ResultPhase 2Immunotherapy

30 Oct 2025

·www.prnewswire.com

Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 40th Anniversary Annual Meeting

MILWAUKEE, Oct. 30, 2025 /PRNewswire/ -- The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based Late-breaking Abstracts. SITC is proud to announce the titles and authors for the clinical Late-breaking Abstracts (LBA) . The abstracts will be presented at SITC's upcoming 40th Anniversary Annual Meeting & Pre-Conference Programs taking place Nov. 5–9, 2025, in National Harbor, MD and virtually. Continue Reading SITC 2025 Logo "We are excited to incorporate these clinical abstracts into an already impressive lineup of abstracts that will be presented at SITC. The Late-breaking Abstracts this year will only focus on late-breaking data from interventional clinical trials in humans and will further enhance the cutting-edge science offered at the 40th Anniversary Annual Meeting," said SITC Vice President Sandra Demaria MD. "SITC is committed to accelerating the approval of 100 novel agents by 2034, and providing a platform to showcase the latest clinical advancements at our Annual Meeting is an important component of this goal." The Late-breaking Abstracts with oral presentations at the 40th Anniversary Annual Meeting are: (1316) Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a Phase 1/2 trial Aurélien Marabelle, MD, PhD – Gustave Roussy & Paris Saclay University Session 104: Clinical Oral Abstract Session – Friday, Nov. 7, 2025 – 11:30 a.m. ET (1342) First-in-human dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and initial efficacy of mRNA-LNP MT-302 in vivo CAR therapy in solid tumors Rasha Cosman, BSc (Med), MBBS, FRACP – St. Vincent's Hospital Session 104: Clinical Oral Abstract Session – Friday, Nov. 7, 2025 – 11:30 a.m. ET (1348) Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment Li Zhang, MD – Sun Yat-Sen University Cancer Center Session 104: Clinical Oral Abstract Session – Friday, Nov. 7, 2025 – 11:30 a.m. ET (1305) Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma (cSCC): results from cohort A of the phase 2 KeyForm-010 study Matteo Carlino, MBBS, PhD, BMedSC, FRACP – The University of Sydney Session 106a: Considerations for Incorporating Biomarkers in Perioperative/Neoadjuvant Therapy – Friday, Nov. 7, 2025 – 1:45 p.m. ET (1346) Molecular and immunologic correlates of response in a phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma Kenneth Tsai, MD, PhD – Moffitt Cancer Center Session 106a: Considerations for Incorporating Biomarkers in Perioperative/Neoadjuvant Therapy – Friday, Nov. 7, 2025 – 1:45 p.m. ET (1327) Biomarker and updated clinical data for RP1 plus nivolumab in anti-PD-1-failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade Trisha Wise-Draper, MD, PhD– University of Cincinnati Cancer Center Session 107d: The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics – Friday, Nov. 7, 2025 – 3:55 p.m. ET (1328) SSGJ-707, a PD-1/VEGF bispecific antibody, combined with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC): results from a phase 2 study Lin Wu, PhD –Hunan Cancer Hospital Session 107d: The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics – Friday, Nov. 7, 2025 – 3:55 p.m. ET (1310) A phase 1/IIa study of ILKN421H, a LNP mRNA encoding an IL2Rβγ selective IL-2v, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors Haining Huang, PhD- ILeukon Therapeutics Session 206: Clinical Oral Abstract Session – Saturday, Nov. 8, 2025 – 1:45 p.m. ET (1325) SCOPE, an open label phase 2 parallel multi cohort clinical trial evaluating an off-the-shelf DNA plasmid vaccine in first line advanced melanoma combined with check point blockade - interim read-out Nermeen Varawalla, MD, PhD, MBA – Scancell Ltd Session 206: Clinical Oral Abstract Session – Saturday, Nov. 8, 2025 – 1:45 p.m. ET (1336) Final ph1b/2 results for Nous-209 monotherapy in Lynch syndrome carriers: Annual revaccination boosts T cell immunity informing future cancer interception strategies Anna Morena D'Alise, PhD – Nouscom SRL Session 206: Clinical Oral Abstract Session – Saturday, Nov. 8, 2025 – 1:45 p.m. ET (1340) Lead-in therapy targeting PD1 and/or LAG3 distinguishes differential impacts upon the immune response in first-line treatment of metastatic melanoma Lilit Karapetyan, MD – Moffitt Cancer Center Session 206: Clinical Oral Abstract Session – Saturday, Nov. 8, 2025 – 1:45 p.m. ET (1345) Initial phase 1a/1b results of STK-012, an α/β IL-2 receptor biased partial agonist, with pembrolizumab, pemetrexed, and carboplatin in 1L PD-L1 negative non-squamous NSCLC Adam Schoenfeld, MD – Memorial Sloan-Kettering Cancer Center Session 206: Clinical Oral Abstract Session – Saturday, Nov. 8, 2025 – 1:45 p.m. ET The full Regular and Young Investigator Award abstracts will be available on Nov. 4 at 9 a.m. ET and LBA – Clinical Only abstracts will be made available on Nov. 7 at 9 a.m. ET. Both types of abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC) Clinical Late-breaking Abstract Sessions with oral abstract presentations will take place on Friday, Nov. 7 from 11:30 a.m.–12:15 p.m. CT and Saturday, Nov. 8 from 1:45–3 p.m. ET in the Gaylord National Resort and Convention Center - Ballroom Level - Potomac Ballroom. In addition, Late-breaking Abstract posters will be presented in the Exhibit and Poster Hall and the virtual ePoster Hall beginning Friday, Nov. 7 at 10 a.m. ET. To learn more about the Late-breaking Abstracts, visit the 40th Annual Meeting & Pre-Conference Programs website. To register for the 40th Anniversary Annual Meeting and Pre-Conference Programs, click here. About SITC The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere. To learn more, visit and follow us on X, LinkedIn, Facebook and YouTube. SOURCE Society for Immunotherapy of Cancer (SITC) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Clinical ResultImmunotherapyVaccine

100 Deals associated with SSGJ-707

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic Colorectal Carcinoma	Phase 3	-	Pfizer Inc.	12 Dec 2025
Advanced Lung Non-Small Cell Carcinoma	Phase 3	-	Pfizer Inc.	05 Dec 2025
metastatic non-small cell lung cancer	Phase 3	-	Pfizer Inc.	05 Dec 2025
Extensive stage Small Cell Lung Cancer	Phase 3	-	Pfizer Inc.	17 Nov 2025
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Shenyang Sunshine Pharmaceuticals Co., Ltd.	20 Jun 2025
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	China	Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd.	16 May 2025
Advanced Renal Cell Carcinoma	Phase 2	-	Pfizer Inc.	04 Dec 2025
Locally Advanced Renal Cell Carcinoma	Phase 2	-	Pfizer Inc.	04 Dec 2025
Metastatic Clear Cell Renal Cell Carcinoma	Phase 2	-	Pfizer Inc.	04 Dec 2025
Metastatic Renal Cell Carcinoma	Phase 2	-	Pfizer Inc.	04 Dec 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06493760 (ESMO 12025 \| ESMO 22025) Manual	Phase 2	Metastatic Colorectal Carcinoma First line Proficient DNA Mismatch Repair (pMMR) \| Microsatellite Stable (MSS)	68	SSGJ-707 + Chemotherapy (10mg/kg Q3W + XELOX)	gumzrpfxpi(tdzwjmxhmu) = irqlhorkqu krkysnpwni (jidjlqarmq ) View more	Positive	13 Oct 2025
				SSGJ-707 + Chemotherapy (10mg/kg Q2W + mFOLFOX6)	gumzrpfxpi(tdzwjmxhmu) = cypbrodzfl krkysnpwni (jidjlqarmq ) View more
NCT06361927 (SSGJ-707-NSCLC-II-01, ASCO2025)	Phase 2	Non-Small Cell Lung Cancer	83	SSGJ-707 5mg/kg Q3W	cfnmnsiucc(ddfghshsll) = 6% of pts experienced TRAE leading to discontinuation kdudaakjwx (mgydhbbfmz ) View more	Positive	30 May 2025
				SSGJ-707 10mg/kg Q3W
NCT06361927 (Corporate Publications) Manual	Phase 2	PD-L1 positive Non-Small Cell Lung Cancer PD-L1 High Expression (TPS >= 1%)	83	SSGJ-707 10 mg/kg Q3W	tezdihugny(ldbzpgwhgi) = iytcujbhga vqwxrfginc (xgdqpcsuig ) View more	Positive	16 Jan 2025
NCT06493760 (Corporate Publications) Manual	Phase 2	Colorectal Cancer First line \| Last line \| Third line	68	SSGJ-707	juvpzbkqmc(xbqhzexfnh) = zsukozjlkl rxwojttbiv (ldfaeqcuyh ) View more	Positive	16 Jan 2025
				SSGJ-707 + chemo	juvpzbkqmc(xbqhzexfnh) = fmjbnkltyx rxwojttbiv (ldfaeqcuyh ) View more
CTR20221432 (Corporate Publications) Manual	Phase 1/2	Advanced Malignant Solid Neoplasm	85	SSGJ-707	lgcnxojfsx(eiuaddfabr) = klhftpnhuu wiltqgurww (ydmtqdhxrb ) View more	Positive	16 Jan 2025
NCT06412471 (Corporate Publications) Manual	Phase 2	Non-Small Cell Lung Cancer First line without EGFR/ALK alterations	108	SSGJ-707 + chemotherapy (NSQ)	qjhvriaxpq(uqudwklsts) = ewsxyxvvqs nduoyrpkkt (ubtoiyunup ) View more	Positive	16 Jan 2025
				SSGJ-707 + chemotherapy (SQ)	qjhvriaxpq(uqudwklsts) = kzzikmhsau nduoyrpkkt (ubtoiyunup ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

SSGJ-707

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation